{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:40:21Z","timestamp":1794559221128,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001449"],"award-info":[{"award-number":["UL1TR001449"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01HL131696"],"award-info":[{"award-number":["R01HL131696"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["P51OD011107"],"award-info":[{"award-number":["P51OD011107"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Elevated low-density lipoprotein cholesterol (LDL-C) is an important risk factor in the development of atherosclerotic cardiovascular disease (ASCVD). Inhibitors of proprotein convertase subtilisin\/kexin type 9 (PCSK9), a negative regulator of LDL-C metabolism, have emerged as promising approaches for reducing elevated LDL-C levels. Here, we evaluated the cholesterol-lowering efficacy of virus-like particle (VLP) based vaccines that target epitopes found within the LDL receptor (LDL-R) binding domain of PCSK9. In both mice and non-human primates, a bivalent VLP vaccine targeting two distinct epitopes on PCSK9 elicited strong and durable antibody responses and lowered cholesterol levels. In macaques, a VLP vaccine targeting a single PCSK9 epitope was only effective at lowering LDL-C levels in combination with statins, whereas immunization with the bivalent vaccine lowered LDL-C without requiring statin co-administration. These data highlight the efficacy of an alternative, vaccine-based approach for lowering LDL-C.<\/jats:p>","DOI":"10.1038\/s41541-023-00743-6","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:01:39Z","timestamp":1695862899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates"],"prefix":"10.1038","volume":"8","author":[{"given":"Alexandra","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-1337","authenticated-orcid":false,"given":"Koen K. A.","family":"Van Rompay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-250X","authenticated-orcid":false,"given":"Maureen","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9408-3991","authenticated-orcid":false,"given":"Jennifer K.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie L.","family":"Usachenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Immareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie M.","family":"Lovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5712-4739","authenticated-orcid":false,"given":"Bryce","family":"Chackerian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"743_CR1","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao, C. W. et al. Heart Disease and Stroke Statistics-2022 update: a report from the American Heart Association. Circulation 145, e153\u2013e639 (2022).","journal-title":"Circulation"},{"key":"743_CR2","unstructured":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 290, 140\u2013205 (2019)."},{"key":"743_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Boren","year":"2020","unstructured":"Boren, J. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 41, 2313\u20132330 (2020).","journal-title":"Eur. Heart J."},{"key":"743_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670\u20131681 (2010).","journal-title":"Lancet"},{"key":"743_CR5","first-page":"e1046","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139, e1046\u2013e1081 (2019).","journal-title":"Circulation"},{"key":"743_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(19)31950-6","volume":"394","author":"KK Ray","year":"2019","unstructured":"Ray, K. K., Corral, P., Morales, E. & Nicholls, S. J. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet 394, 697\u2013708 (2019).","journal-title":"Lancet"},{"key":"743_CR7","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","volume":"37","author":"PM Ridker","year":"2016","unstructured":"Ridker, P. M., Mora, S., Rose, L. & Group, J. T. S. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur. Heart J. 37, 1373\u20131379 (2016).","journal-title":"Eur. Heart J."},{"key":"743_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00228-015-1994-9","volume":"72","author":"S Trompet","year":"2016","unstructured":"Trompet, S. et al. Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies. Eur. J. Clin. Pharmacol. 72, 431\u2013437 (2016).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"743_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1517\/14740338.5.5.651","volume":"5","author":"A Tiwari","year":"2006","unstructured":"Tiwari, A., Bansal, V., Chugh, A. & Mookhtiar, K. Statins and myotoxicity: a therapeutic limitation. Expert Opin. Drug Saf. 5, 651\u2013666 (2006).","journal-title":"Expert Opin. Drug Saf."},{"key":"743_CR10","doi-asserted-by":"crossref","unstructured":"Sun, L., Wolska, A., Amar, M., Zubiran, R. & Remaley, A. T. Approach to the patient with a suboptimal statin response: causes and algorithm for clinical management. J. Clin. Endocrinol. Metab. 108, 2424\u20132434 (2023).","DOI":"10.1210\/clinem\/dgad153"},{"key":"743_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pharmthera.2014.07.004","volume":"145","author":"AD Marais","year":"2015","unstructured":"Marais, A. D., Kim, J. B., Wasserman, S. M. & Lambert, G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacol. Ther. 145, 58\u201366 (2015).","journal-title":"Pharmacol. Ther."},{"key":"743_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154\u2013156 (2003).","journal-title":"Nat. Genet."},{"key":"743_CR13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264\u20131272 (2006).","journal-title":"N. Engl. J. Med."},{"key":"743_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao, Z. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514\u2013523 (2006).","journal-title":"Am. J. Hum. Genet."},{"key":"743_CR15","doi-asserted-by":"crossref","unstructured":"Brandts, J. & Ray, K. K. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nat. Rev. Cardiol. 20, 600\u2013616 (2023).","DOI":"10.1038\/s41569-023-00860-8"},{"key":"743_CR16","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489\u20131499 (2015).","journal-title":"N. Engl. J. Med."},{"key":"743_CR17","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine, M. S. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500\u20131509 (2015).","journal-title":"N. Engl. J. Med."},{"key":"743_CR18","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 379, 2097\u20132107 (2018).","journal-title":"N. Engl. J. Med."},{"key":"743_CR19","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","volume":"138","author":"KK Ray","year":"2018","unstructured":"Ray, K. K. et al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1. Circulation 138, 1304\u20131316 (2018).","journal-title":"Circulation"},{"key":"743_CR20","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1210\/clinem\/dgac708","volume":"108","author":"CB Newman","year":"2023","unstructured":"Newman, C. B. & Tobert, J. A. Targeting PCSK9 with antibodies and gene silencing to reduce LDL cholesterol. J. Clin. Endocrinol. Metab. 108, 784\u2013790 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"743_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40256-022-00534-9","volume":"22","author":"NR Desai","year":"2022","unstructured":"Desai, N. R. et al. Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis. Am. J. Cardiovasc. Drugs 22, 545\u2013556 (2022).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"743_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/M18-3632","volume":"170","author":"MA Hlatky","year":"2019","unstructured":"Hlatky, M. A. A pound of prevention? Assessing the value of new cholesterol-lowering drugs. Ann. Intern. Med. 170, 264\u2013265 (2019).","journal-title":"Ann. Intern. Med."},{"key":"743_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40273-018-0671-0","volume":"36","author":"MJ Korman","year":"2018","unstructured":"Korman, M. J., Retterstol, K., Kristiansen, I. S. & Wisloff, T. Are PCSK9 inhibitors cost effective? Pharmacoeconomics 36, 1031\u20131041 (2018).","journal-title":"Pharmacoeconomics"},{"key":"743_CR24","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1093\/eurheartj\/ehy147","volume":"39","author":"U Landmesser","year":"2018","unstructured":"Landmesser, U. et al. New prospects for PCSK9 inhibition? Eur. Heart J. 39, 2600\u20132601 (2018).","journal-title":"Eur. Heart J."},{"key":"743_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrd1284","volume":"3","author":"MF Bachmann","year":"2004","unstructured":"Bachmann, M. F. & Dyer, M. R. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov. 3, 81\u201388 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"743_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1586\/14760584.2016.1159136","volume":"15","author":"B Chackerian","year":"2016","unstructured":"Chackerian, B. & Frietze, K. M. Moving towards a new class of vaccines for non-infectious chronic diseases. Expert Rev. Vaccines 15, 561\u2013563 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"743_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-pharmtox-061008-103129","volume":"49","author":"GT Jennings","year":"2009","unstructured":"Jennings, G. T. & Bachmann, M. F. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu. Rev. Pharmacol. Toxicol. 49, 303\u2013326 (2009).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"743_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HJH.0b013e32800ff5d6","volume":"25","author":"PM Amb\u00fchl","year":"2007","unstructured":"Amb\u00fchl, P. M. et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J. Hypertens. 25, 63\u201372 (2007).","journal-title":"J. Hypertens."},{"key":"743_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","volume":"7","author":"MR Farlow","year":"2015","unstructured":"Farlow, M. R. et al. Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer\u2019s disease. Alzheimers Res. Ther. 7, 23 (2015).","journal-title":"Alzheimers Res. Ther."},{"key":"743_CR30","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","volume":"33","author":"E Crossey","year":"2015","unstructured":"Crossey, E. et al. A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 33, 5747\u20135755 (2015).","journal-title":"Vaccine"},{"key":"743_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1172\/JCI116663","volume":"92","author":"S Ishibashi","year":"1993","unstructured":"Ishibashi, S. et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883\u2013893 (1993).","journal-title":"J. Clin. Invest."},{"key":"743_CR32","doi-asserted-by":"crossref","unstructured":"Goksoyr, L. et al. A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines. Vaccines (Basel) 11, 2 (2022).","DOI":"10.3390\/vaccines11010002"},{"key":"743_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13069-w","volume":"7","author":"Y Pan","year":"2017","unstructured":"Pan, Y. et al. A therapeutic peptide vaccine against PCSK9. Sci. Rep. 7, 12534 (2017).","journal-title":"Sci. Rep."},{"key":"743_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.7150\/ijbs.3524","volume":"8","author":"L Zhang","year":"2012","unstructured":"Zhang, L. et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int. J. Biol. Sci. 8, 310\u2013327 (2012).","journal-title":"Int. J. Biol. Sci."},{"key":"743_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1600-065X.2010.00912.x","volume":"236","author":"IJ Amanna","year":"2010","unstructured":"Amanna, I. J. & Slifka, M. K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol. Rev. 236, 125\u2013138 (2010).","journal-title":"Immunol. Rev."},{"key":"743_CR36","doi-asserted-by":"publisher","first-page":"9820","DOI":"10.1073\/pnas.0903849106","volume":"106","author":"JC Chan","year":"2009","unstructured":"Chan, J. C. et al. A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl Acad. Sci. USA 106, 9820\u20139825 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"743_CR37","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.metabol.2010.12.012","volume":"60","author":"R Shamekh","year":"2011","unstructured":"Shamekh, R. et al. Endogenous and diet-induced hypercholesterolemia in nonhuman primates: effects of age, adiposity, and diabetes on lipoprotein profiles. Metabolism 60, 1165\u20131177 (2011).","journal-title":"Metabolism"},{"key":"743_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","volume":"58","author":"Z Awan","year":"2012","unstructured":"Awan, Z. et al. Rosuvastatin, proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin. Chem. 58, 183\u2013189 (2012).","journal-title":"Clin. Chem."},{"key":"743_CR39","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet, S. et al. NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279, 48865\u201348875 (2004).","journal-title":"J. Biol. Chem."},{"key":"743_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","volume":"49","author":"HE Careskey","year":"2008","unstructured":"Careskey, H. E. et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9. J. Lipid Res. 49, 394\u2013398 (2008).","journal-title":"J. Lipid Res."},{"key":"743_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1586\/14760584.6.3.381","volume":"6","author":"B Chackerian","year":"2007","unstructured":"Chackerian, B. Virus-like particles: flexible platforms for vaccine development. Expert Rev. Vaccines 6, 381\u2013390 (2007).","journal-title":"Expert Rev. Vaccines"},{"key":"743_CR42","doi-asserted-by":"publisher","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","volume":"9","author":"G Galabova","year":"2014","unstructured":"Galabova, G. et al. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS ONE 9, e114469 (2014).","journal-title":"PLoS ONE"},{"key":"743_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1457-8","volume":"17","author":"AA Momtazi-Borojeni","year":"2019","unstructured":"Momtazi-Borojeni, A. A., Jaafari, M. R., Badiee, A., Banach, M. & Sahebkar, A. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis. BMC Med. 17, 223 (2019).","journal-title":"BMC Med."},{"key":"743_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1194\/jlr.M019927","volume":"53","author":"W Yin","year":"2012","unstructured":"Yin, W. et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J. Lipid Res. 53, 51\u201365 (2012).","journal-title":"J. Lipid Res."},{"key":"743_CR45","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1128\/JVI.78.8.4037-4047.2004","volume":"78","author":"B Chackerian","year":"2004","unstructured":"Chackerian, B., Briglio, L., Albert, P. S., Lowy, D. R. & Schiller, J. T. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian\/human immunodeficiency virus. J. Virol. 78, 4037\u20134047 (2004).","journal-title":"J. Virol."},{"key":"743_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI11849","volume":"108","author":"B Chackerian","year":"2001","unstructured":"Chackerian, B., Lowy, D. R. & Schiller, J. T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108, 415\u2013423 (2001).","journal-title":"J. Clin. Invest."},{"key":"743_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/clc.22713","volume":"40","author":"SJ Baum","year":"2017","unstructured":"Baum, S. J. et al. PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. Clin. Cardiol. 40, 243\u2013254 (2017).","journal-title":"Clin. Cardiol."},{"key":"743_CR48","doi-asserted-by":"crossref","unstructured":"Gennemark, P. et al. An oral antisense oligonucleotide for PCSK9 inhibition. Sci. Transl. Med. 13, eabe9117 (2021).","DOI":"10.1126\/scitranslmed.abe9117"},{"key":"743_CR49","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.clinthera.2015.09.004","volume":"37","author":"T Turner","year":"2015","unstructured":"Turner, T. & Stein, E. A. Non-statin treatments for managing LDL cholesterol and their outcomes. Clin. Ther. 37, 2751\u20132769 (2015).","journal-title":"Clin. Ther."},{"key":"743_CR50","doi-asserted-by":"publisher","first-page":"13796","DOI":"10.1021\/acs.jmedchem.0c01084","volume":"63","author":"C Alleyne","year":"2020","unstructured":"Alleyne, C. et al. Series of novel and highly potent cyclic peptide PCSK9 inhibitors derived from an mRNA display screen and optimized via structure-based design. J. Med. Chem. 63, 13796\u201313824 (2020).","journal-title":"J. Med. Chem."},{"key":"743_CR51","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne, C. M. et al. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J. Am. Coll. Cardiol. 81, 1553\u20131564 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"743_CR52","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429\u2013434 (2021).","journal-title":"Nature"},{"key":"743_CR53","doi-asserted-by":"publisher","first-page":"e0191895","DOI":"10.1371\/journal.pone.0191895","volume":"13","author":"R Kawakami","year":"2018","unstructured":"Kawakami, R. et al. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice. PLoS ONE 13, e0191895 (2018).","journal-title":"PLoS ONE"},{"key":"743_CR54","doi-asserted-by":"crossref","unstructured":"Momtazi-Borojeni, A. A. et al. Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates. Vaccines (Basel) 9, 749 (2021).","DOI":"10.3390\/vaccines9070749"},{"key":"743_CR55","doi-asserted-by":"crossref","unstructured":"Ortega-Rivera, O. A., Pokorski, J. K. & Steinmetz, N. F. A single-dose, implant-based, trivalent virus-like particle vaccine against \u201ccholesterol checkpoint\u201d proteins. Adv. Ther. (Weinh) 4, 2100014 (2021).","DOI":"10.1002\/adtp.202100014"},{"key":"743_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10557-020-07041-6","volume":"35","author":"D Wu","year":"2021","unstructured":"Wu, D. et al. PCSK9Qbeta-003 vaccine attenuates atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc. Drugs Ther. 35, 141\u2013151 (2021).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"743_CR57","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00228-021-03149-2","volume":"77","author":"M Zeitlinger","year":"2021","unstructured":"Zeitlinger, M. et al. A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. Eur. J. Clin. Pharmacol. 77, 1473\u20131484 (2021).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"743_CR58","doi-asserted-by":"crossref","unstructured":"Chackerian, B. & Peabody, D. S. Factors that govern the induction of long-lived antibody responses. Viruses 12, 74 (2020).","DOI":"10.3390\/v12010074"},{"key":"743_CR59","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone, N. J. et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1\u2013S45 (2014).","journal-title":"Circulation"},{"key":"743_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00274-4","volume":"6","author":"L Jelinkova","year":"2021","unstructured":"Jelinkova, L. et al. An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein. NPJ Vaccines 6, 13 (2021).","journal-title":"NPJ Vaccines"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00743-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00743-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00743-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T19:10:39Z","timestamp":1700421039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00743-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00743-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.05.15.540560","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.C. has an equity stake in Metaphore Biotechnologies. A.F. is currently an employee of Moderna, Inc. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}